There are currently 56 clinical trials in Centennial, Colorado looking for participants to engage in research studies. Trials are conducted at various facilities, including Rocky Mountain Cancer Centers - Centennial, IMMUNOe Research Centers, Teva Investigational Site 1090 and IMMUNOe International Research Centers. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
NCT04462406
Recruiting
This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for patients with unresectable melanoma. This trial is being done to determine if doctors can safely shorten the use of standard of care anti-PD1 therapy for melanoma by using biomarkers seen on PET/CT imaging and tumor biopsy.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Rocky Mountain Cancer Centers - Centennial, Centennial, Colorado
Conditions: Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
Register for Updates
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT03937635
Recruiting
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Rocky Mountain Cancer Centers - Centennial, Centennial, Colorado
Conditions: Smoldering Plasma Cell Myeloma
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Rocky Mountain Cancer Centers - Centennial, Centennial, Colorado
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites
NCT04288921
Recruiting
A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx Influenza A/B + RSV Test at Point of Care Testing Sites
Gender:
All
Ages:
All
Trial Updated:
03/10/2023
Locations: ImmunoE Health and Research, Centennial, Colorado
Conditions: Influenza, Human, Respiratory Syncytial Virus Infections
Register for Updates
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647
Recruiting
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2022
Locations: Rocky Mountain Cancer Centers - Centennial, Centennial, Colorado
Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates
An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)
NCT05070455
Recruiting
This is a Phase IV, multicenter, open-label study of Asceniv™ administered as an intravenous infusion of Asceniv™ (IGIV) 300-800 mg/kg every 21 or 28 days in approximately 12 pediatric subjects with Primary Immunodeficiency Diseases (PIDD). The study will be conducted at 5-7 centers in the United States, with subjects receiving six (28 day cycle) or seven (21 day cycle) doses of Asceniv™ during the study.
Gender:
All
Ages:
Between 2 years and 11 years
Trial Updated:
09/13/2022
Locations: Immunoe Research Centers, Centennial, Colorado
Conditions: Primary Immune Deficiency
Register for Updates
Home Based Infusions for Ocrelizumab
NCT04650321
Recruiting
The goal is to assess the safety and effectiveness of home ocrelizumab infusion.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
06/08/2021
Locations: Amerita, Centennial, Colorado
Conditions: Multiple Sclerosis
Register for Updates
Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection
NCT04705831
Recruiting
Randomized, Double Blind, Placebo Controlled, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/08/2021
Locations: IMMUNOe Research Centers, Centennial, Colorado
Conditions: Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder), Covid19
Register for Updates